How arteriovenous grafts could help to optimize vascular access management

Area of Science:

• Nephrology
• Vascular Surgery
• Biomaterials Science

Background:

• Traditional arteriovenous fistulae (AVF) often fail due to primary issues, maturation delays, and complications, making them unsuitable for many chronic kidney disease (CKD) patients.
• An aging CKD population and prior venous injuries limit options for successful AVF creation.
• Despite advancements, catheter-related complications persist, highlighting the need for alternatives.

Purpose of the Study:

• To evaluate the role and benefits of arteriovenous grafts (AVG) as a vascular access option in dialysis patients.
• To explore AVG as a superior alternative to AVF in specific patient populations.
• To discuss the potential of novel biomaterials in improving AVG performance.

Main Methods:

• Review of current literature on AVF and AVG outcomes, including failure rates and complications.
• Analysis of patient-specific factors influencing vascular access selection (e.g., age, vein size, dialysis dependence).
• Examination of advancements in graft materials, including biohybrid technologies and xenografts.

Main Results:

• AVF frequently exhibit primary failure and maturation issues, necessitating alternative access.
• Arteriovenous grafts (AVG) present a viable, catheter-sparing option, particularly for patients with inadequate AVF maturation potential.
• Emerging biomaterials, such as xenografts, show comparable or superior performance to traditional AVG materials.

Conclusions:

• An individualized vascular access strategy, considering patient-specific factors and AVG benefits, is essential for optimizing dialysis outcomes.
• Arteriovenous grafts are increasingly recognized as a valuable alternative to AVF in select hemodialysis patients.
• Continued innovation in graft materials promises to further enhance the safety and efficacy of AVG.